Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)

Kristi McIntyre; Joyce O'Shaughnessy; Lee Schwartzberg; Stefan Glück; Erhan Berrak; James X. Song; David Cox; Linda T. Vahdat

doi:10.1007/s10549-014-3010-y

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)

Kristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, Linda T. Vahdat

Braman/Sylvester Comprehensive Cancer Center

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	329
Number of pages	1
Journal	Breast cancer research and treatment
Volume	146
Issue number	2
DOIs	https://doi.org/10.1007/s10549-014-3010-y
State	Published - Jul 2014

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-014-3010-y

Cite this

McIntyre, K., O'Shaughnessy, J., Schwartzberg, L., Glück, S., Berrak, E., Song, J. X., Cox, D., & Vahdat, L. T. (2014). Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9). Breast cancer research and treatment, 146(2), 329. https://doi.org/10.1007/s10549-014-3010-y

Erratum to : Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9). / McIntyre, Kristi; O'Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak, Erhan; Song, James X.; Cox, David; Vahdat, Linda T.

In: Breast cancer research and treatment, Vol. 146, No. 2, 07.2014, p. 329.

Research output: Contribution to journal › Comment/debate › peer-review

McIntyre, K, O'Shaughnessy, J, Schwartzberg, L, Glück, S, Berrak, E, Song, JX, Cox, D & Vahdat, LT 2014, 'Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)', Breast cancer research and treatment, vol. 146, no. 2, pp. 329. https://doi.org/10.1007/s10549-014-3010-y

McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song JX et al. Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9). Breast cancer research and treatment. 2014 Jul;146(2):329. https://doi.org/10.1007/s10549-014-3010-y

McIntyre, Kristi ; O'Shaughnessy, Joyce ; Schwartzberg, Lee ; Glück, Stefan ; Berrak, Erhan ; Song, James X. ; Cox, David ; Vahdat, Linda T. / Erratum to : Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9). In: Breast cancer research and treatment. 2014 ; Vol. 146, No. 2. pp. 329.

@article{ed224ae96d3b46efbcf576afc1b1f0cb,

title = "Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)",

author = "Kristi McIntyre and Joyce O'Shaughnessy and Lee Schwartzberg and Stefan Gl{\"u}ck and Erhan Berrak and Song, {James X.} and David Cox and Vahdat, {Linda T.}",

year = "2014",

month = jul,

doi = "10.1007/s10549-014-3010-y",

language = "English (US)",

volume = "146",

pages = "329",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Erratum to

T2 - Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)

AU - McIntyre, Kristi

AU - O'Shaughnessy, Joyce

AU - Schwartzberg, Lee

AU - Glück, Stefan

AU - Berrak, Erhan

AU - Song, James X.

AU - Cox, David

AU - Vahdat, Linda T.

PY - 2014/7

Y1 - 2014/7

UR - http://www.scopus.com/inward/record.url?scp=84904092814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904092814&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3010-y

DO - 10.1007/s10549-014-3010-y

M3 - Comment/debate

AN - SCOPUS:84904092814

VL - 146

SP - 329

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-014-2923-9)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this